IOL Chemicals & Pharmaceuticals Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/nljcdepwi9vcxufmbbin3z0l.pdf

Key Takeaways


Revenue & Margin Drivers

Mahajan: "The prices are already bottomed out and we are getting regular order at certain prices of ibuprofen. So, we do not fear any more reduction of prices in Ibuprofen."

Segment Performance

SegmentTrendCommentary
Pharmaceuticals▬ Margin heldEBIT margin maintained at 11.8% as operating expenses eased, despite the revenue decline.
Specialty Chemicals▲ Inching positiveEBIT margin was only 1% in Q1, but the segment has turned positive at the bottom line over the last 2-3 quarters after earlier losses. Acetic anhydride was launched last year to add value; ethyl acetate received REACH certification.
Ibuprofen▼ Price pressurePrices declined from ~$12 four years ago to $9-$10 now. Capacity utilization rose from ~65% in 2022 to 75-85% in FY24, cushioning the revenue impact.
Non-ibuprofen APIs▲ Volume, ▼ PriceCapacity utilization improved from ~25% two years ago to ~52% last year to ~59-60% now. But revenue is stuck at ~₹95-100 crore per quarter because Paracetamol and Metformin prices collapsed. Paracetamol contribution is now not more than 10-12% of the non-ibuprofen segment after the company intentionally reduced some capacity.

Non-Ibuprofen Strategy & Capacity Ramp

Singh: "If we put those rates at today's quantities, it is going to cross Rs. 600 crore in FY2024. So, we were not knowing that how the prices are going to reduce and prices reduced very substantially for Paracetamol, Metformin and other products also."

Export & Regulatory Pathway

Singh: "Perhaps this is not their priority. So, that is why they are not inspecting a company like us as of now. But whenever they inspect, most of the filed DMF's for 15 drugs may be considered as US FDA approved at one go."

Competitive Dynamics & SI Group Exit


Capital Allocation & Balance Sheet

Singh: "Our priority as of now is to have the business increase at a higher level than considering for buyback."

Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin13% to 15%"Near future"
API price recoveryParacetamol and Metformin prices bottomed out, expected to move northward1-2 quarters
Non-ibuprofen revenue share50% of API segment turnover3-4 years
Capacity utilizationRamp to optimum level, pending regulatory approvals (all except US FDA)Within 2 years
Export revenue shareIncrease from ~30% to 45-50%3-4 years
Revenue growth~10% increase in current year, with >10% from volume and 5-10% from priceCurrent fiscal year
Export query conversionImprovement from increased queries and audits3-4 quarters
Other expensesPower/fuel and repair/maintenance sustained at current levelsGoing forward

Key Metrics

MetricQ1 FY25
Total income₹510 cr, vs ₹570 cr in Q1 FY24 and ₹511 cr in Q4 FY24
EBITDA₹58 cr, vs ₹80 cr in Q1 FY24 and ₹58 cr in Q4 FY24
EBITDA margin11.4%, down 260 bps YoY from 14%, vs 11.3% in Q4 FY24
Net profit₹30 cr, vs ₹46 cr in Q1 FY24 and ₹28 cr in Q4 FY24
EBIT margin – Pharmaceutical segment11.8%
EBIT margin – Specialty Chemical segment1%
Export revenue₹150 cr, vs ₹149 cr in Q1 FY24; 30% of total turnover
Revenue growth guidance (FY25)10% increase, volume growth more than 10%, price growth 5-10%
EBITDA margin guidance (near future)13% to 15%
Ibuprofen capacity utilization~80%
Non-ibuprofen capacity utilization~59% to 60% on average, minimum 52% product-to-product; up from ~52% last year and ~25% two years back
Non-ibuprofen revenue run rate~₹95-100 cr per quarter, flattish over last 3 quarters
Paracetamol price declineMore than 40% in the last 1 year
Metformin price decline15% to 20%
Net cash~₹190 cr as on 30th June 2024
CAPEX target FY25~₹200 cr
CAPEX target FY26~₹150 cr
Peak revenue potential at current rates~₹2,400 to ₹2,500 cr
Export revenue target45% to 50% of total revenue, in 3-4 years